Wedbush Increases Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $55.00

Dianthus Therapeutics (NASDAQ:DNTH) had its price objective increased by research analysts at Wedbush from $46.00 to $55.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Wedbush’s target price indicates a potential upside of 15.84% from the stock’s previous close.

Other equities research analysts also recently issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, January 21st. Truist Financial increased their target price on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Jefferies Financial Group raised their price objective on shares of Dianthus Therapeutics from $66.00 to $81.00 and gave the company a “buy” rating in a research report on Monday, February 2nd. Finally, HC Wainwright increased their price objective on Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $67.63.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH opened at $47.48 on Wednesday. Dianthus Therapeutics has a 52 week low of $13.36 and a 52 week high of $57.50. The business has a 50 day simple moving average of $44.95 and a 200 day simple moving average of $36.87. The stock has a market cap of $2.05 billion, a price-to-earnings ratio of -13.64 and a beta of 1.59.

Insider Transactions at Dianthus Therapeutics

In other Dianthus Therapeutics news, CFO Ryan Savitz sold 20,000 shares of the firm’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $45.18, for a total value of $903,600.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 8.15% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DNTH. Parkside Financial Bank & Trust increased its position in Dianthus Therapeutics by 131.7% during the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock valued at $37,000 after purchasing an additional 540 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Dianthus Therapeutics in the 2nd quarter valued at about $27,000. Russell Investments Group Ltd. bought a new stake in Dianthus Therapeutics in the 3rd quarter valued at about $64,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Dianthus Therapeutics in the fourth quarter worth approximately $135,000. Finally, Tower Research Capital LLC TRC grew its holdings in Dianthus Therapeutics by 330.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after buying an additional 3,317 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.